Allergan plc and Gedeon Richter Plc announced they will present data on the investigational drug cariprazine in patients with schizophrenia and acute mania in bipolar I disorder during the 28th European College of Neuropsychopharmacology (ECNP) annual congress in Amsterdam, to be held from August 29 – September 1, 2015.
Data presented include the first detailed results of cariprazine for the potential treatment of schizophrenia patients with predominant negative symptoms.
Cariprazine, an investigational drug, is an atypical antipsychotic being developed for the treatment of patients with schizophrenia and for patients with manic or mixed episodes associated with bipolar I disorder. The safety and efficacy of cariprazine was studied in a clinical trial programme of more than 2,700 patients with these conditions. In addition, cariprazine is being investigated for the treatment of bipolar depression and adjunctive major depressive disorder (MDD) in adults. Cariprazine was discovered and co-developed by Gedeon Richter Plc and is licensed to Actavis, now Allergan, in the US and Canada.
Gedeon Richter Plc, headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe.
Allergan plc is a unique, global pharmaceutical company and a leader in a new industry model – growth pharma.